PeloBiotech

www.pelobiotech.com
GMP iPS cells
GMP iPSCs are high-quality induced pluripotent stem cells derived from adult tissue biopsies, suitable for therapeutic
applications. They meet strict regulatory standards to ensure their safety and effectiveness for human use.
• We use StemRNA Reprogramming Technology, which is virus-free and complies with regulatory guidelines.
• Benefits include iPSCs manufactured according to ICH 5QA standards, generated with footprint-free RNA
reprogramming technology, and available for commercial use.
• Diverse donors and over 30 years of experience in human tissue procurement.
• StemRNA Reprogramming Technology produces robust iPSCs with low batch-to-batch variation,
eliminating the need for screening exogenous genes.
• Our iPSC seed stocks, Master Cell Banks, and working cell banks are suitable for commercial and therapeutic
applications.
iPS derived cells
We use human iPSC technology, to create a wide range of cell models and biosensor technologies. Our capabilities cater
to various applications, spanning preclinical drug discovery, biobanking, in vitro diagnostics, and biomarker
development.
Induced pluripotent stem (iPS) cells offer several advantages and serve as a superior human disease model compared to
animal cells for several reasons:
• Human Relevance: iPS cells are derived from human tissues, making them more relevant for studying human
diseases. This is crucial because human physiology and disease mechanisms can differ significantly from those
of animals.
• Patient-Specific Modeling: iPS cells can be generated from individual patients, allowing the creation of patientspecific
disease models. This is invaluable for studying genetic diseases and understanding the unique aspects
of a patient's condition.
• Disease Recapitulation: iPS cells can be differentiated into a variety of cell types relevant to the disease being
studied, such as neurons, cardiomyocytes, or hepatocytes. This enables researchers to closely mimic disease
conditions in a dish.
• Genetic Manipulation: iPS cells can be genetically modified to introduce disease-associated mutations or correct
genetic defects. This provides a precise way to investigate the genetic basis of diseases.
• Drug Screening: iPS-derived cells can be used for high-throughput drug screening to identify potential therapies
or test drug efficacy. This is particularly important for personalized medicine.
• Reduced Ethical Concerns: Using iPS cells alleviates many ethical concerns associated with the use of embryonic
stem cells, which can be controversial.
• Consistency: iPS cells provide a consistent and reproducible source of human cells for experimentation,
eliminating genetic variability found in animal models.
• Translation to Clinical Applications: iPS cells have the potential to be used in cell-based therapies and
regenerative medicine, making them a bridge between research and clinical applications.
• Longitudinal Studies: Researchers can derive iPS cells from patients at different stages of a disease and track
the disease progression over time, which is challenging to do with animal models.
• Cost and Time Efficiency: iPS cell-based research is often more cost-effective and less time-consuming than
working with animal models.
The latest applications of induced pluripotent stem cells (iPSCs) encompass a wide array of cutting-edge advancements
in regenerative medicine, disease modeling, drug screening, and cell therapy. These applications have been made possible
by the unique properties of iPSCs, which are similar to embryonic stem cells (ESCs) in terms of morphology, proliferation,
and gene expression profile (Okita & Yamanaka, 2008). iPSC technology has significantly enriched regenerative medicine
by introducing autologous pluripotent progenitor pools bioengineered from ordinary somatic tissue, offering potential in
disease modeling and therapeutic applications (Nelson et al., 2009; Polo et al., 2010). Notably, the first clinical study using
human iPSC-derived cells was initiated in 2014, utilizing human iPSC-derived retinal pigment epithelial (RPE) cells to treat
macular degeneration, resulting in improved vision for the patient (Shi et al., 2016).
Recent advances in differentiating cells such as cardiac, neural, and skeletal muscle cells from iPSCs, as well as directly
reprogramming somatic cells in tissue regeneration applications, have been summarized and synthesized, highlighting the
versatility of iPSCs in various therapeutic contexts (Mao et al., 2022). iPSCs have also been explored for bone
regeneration, cardiovascular disease, and as pre-clinical models for studying human disease, demonstrating their potential
in diverse medical applications (He et al., 2018; Plews et al., 2012; Huang et al., 2020).
9